Skip to content

A pilot study in the effect of mealworm protein on muscle damage in active vital elderly

A pilot study in the effect of mealworm protein on muscle damage in active vital elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21181
Enrollment
69
Registered
2021-11-08
Start date
2022-04-04
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

The subjects will be randomly assigned to a protein or iso-caloric placebo supplement group. The daily supplementation will be consumed at two doses/day, during breakfast and after an exercise bout (o

Sponsors

Radboudumc
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - 60 years of older - Registered for the Nijmegen Four Days Marches 2022 - Able to understand and perform the study procedures

Exclusion criteria

Exclusion criteria: - Type I or Type II diabetes - Allergic or sensitive for milk proteins, or lactose intolerant - Allergic or sensitive for shell and shellfish, like shrimp - BMI >30kg/m2 - Diagnosed COPD - Currently treated for cancer - Diagnosed renal insufficiency - Diagnosed intestinal diseases influencing the uptake of protein (i.e. active inflammatory bowel disease, Crohn’s disease) - Consumption of other freely available protein supplements on their own during the total study period of about 4 months - Use of statins - Involved in a heavy resistance type exercise program

Design outcomes

Primary

MeasureTime frame
To investigate the impact of additional protein intake of the lesser mealworm on muscle damage (serum creatine kinase (CK) and lactate dehydrogenase (LDH)) due to repeated physical exercise (walking 30-50 km) in vital active elderly.

Secondary

MeasureTime frame
The secondary study parameters are body composition, muscle strength, blood lipids and inflammatory markers.

Contacts

Public ContactMarcia Spoelder-Merkens

Radboudumc

marcia.spoelder-merkens@radboudumc.nl0614399980

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)